Horia Bumbea

TL;DR: The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease.

TL;DR: A comprehensive description of these panels, both mandatory and complementary, for both types of clinical conditions is established, and the reason for using each marker, sustained by relevant literature information, is provided in detail.

TL;DR: The most frequently reported grade 3 and grade 4 treatment-related adverse events were increased γ-glutamyltransferase (seven [6%] of 127 patients) and increased alanine aminotransferase (four [3].

TL;DR: This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL and recommends up-front allogeneic hematopoietic stem-cell transplantation and novel agents.

TL;DR: While both variants have a significant contribution, they have nuanced consequences, with JAK2 46/1 predisposing essentially to JAK-2 V617F‐positive MPN, and TERT rs2736100 A>C having a more general, non‐specific effect on all MPn, regardless of phenotype or major molecular subtype.